Stefan Duerr, sr. director, head of the Cenduit Drug Supply Center of Excellence, and IQVIA business, explains how a flexible and innovative approach to Interactive Response Technology (IRT) can help navigate today's clinical trial landscape.
Paul Smaltz, vice president, pharmaceuticals, at Roquette, explores how taking a more ‘human’ look at the issue of drug shortages and supply chain resilience could help the industry find the fresh ideas it needs to tackle this pressing problem.
Dr. Jan Ehlers, chief executive officer at Secop GmbH, shares the trends and challenges in the cold chain industry and the rising demand for vaccine transport solutions.
With the ongoing energy crisis, Rebekah Jordan considers the effect of surging manufacturing costs on the pharma sector in Europe, and pharma's hopes to mitigate production and supply chain issues with resiliency and innovation.
Bomi Group, a UPS Healthcare company, opened its new storage and distribution facility in Madrid following an 18-million-euro investment. This new logistics centre will be one of the largest warehouses in the European pharmaceutical sector.
Rebekah Jordan sat with Kelly Doering, AspenTech, to learn more about how digitalisation in pharma manufacturing is key to overcoming drug shortages such as this one, and how the industry can build a more resilient and flexible supply chain.
Alexander Krujatz, chief commercial officer, Centrient Pharmaceuticals, explains the decreasing resilience of the supply chain of essential drugs to European patients, and what can be done to safeguard the essential medicines for patients in Europe.
EPM fired some quick questions with Juan Guerra, president of International Business Group at AmerisourceBergen, to learn about the increasing market for cold chain products and the future of the biopharma supply chain.
Jeong Jin-hyeok, associated director of Aseptic Filling, at Samsung Biologics, examines the lessons learned following the onset of COVID-19 and highlights how CDMO flexibility is helping to hail in an era of new therapeutic modalities.
Niall Balfour, CEO, Tower Cold Chain, discusses the current challenges in the pharmaceutical cold chain and highlights how pharmaceutical manufacturers can ensure safe delivery of shipments, from mass-market to clinical trials.
